Hyundai Pharm (004310) — Capital Reinvestment Ratio
Latest as of February 2026:
13.77x
Hyundai Pharm (004310) has a Capital Reinvestment Ratio of 13.77x as of February 2026, meaning it reinvests 14% of its operating cash flow (₩188.28 Million) in capital expenditures (₩2.59 Billion). See 004310 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
13.77x
Capex / Operating Cash Flow
Operating Cash Flow
₩188.28 Million
KRW
Capital Expenditures
₩2.59 Billion
KRW
Data as of
Feb 2026
Most recent filing
Hyundai Pharm Capital Reinvestment Ratio (2010–2022)
This chart tracks Hyundai Pharm's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Hyundai Pharm (2010–2022)
Year-by-year Capital Reinvestment Ratio for Hyundai Pharm from 2010 to 2022. For live market cap and broader valuation context, see market cap of Hyundai Pharm.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.57x | ₩11.62 Billion | ₩6.58 Billion | ▼ -57.3% |
| 2021 | 1.33x | ₩5.13 Billion | ₩6.81 Billion | ▲ +123.9% |
| 2020 | 0.59x | ₩10.80 Billion | ₩6.40 Billion | ▲ +74.8% |
| 2019 | 0.34x | ₩6.96 Billion | ₩2.36 Billion | ▼ -64.0% |
| 2018 | 0.94x | ₩2.83 Billion | ₩2.67 Billion | ▲ +233.7% |
| 2013 | 0.28x | ₩7.95 Billion | ₩2.24 Billion | ▼ -52.0% |
| 2011 | 0.59x | ₩6.27 Billion | ₩3.68 Billion | ▼ -60.1% |
| 2010 | 1.47x | ₩2.68 Billion | ₩3.95 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow